Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Background and Rationale
Raltegravir and Maraviroc, the first in class of 2 new families of antiretroviral drugs have
demonstrated a high potency in treatment experienced and naive patients. Both drugs appeared
well tolerated with low metabolic toxicity. No data are currently available concerning the
combination of these 2 drugs.
Hypothesis
Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive
patients infected by CCR5 HIV-1 previously treated for 6 months with a
Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination.